Published in final edited form as:

J Rheumatol. 2012 February ; 39(2): 262–268. doi:10.3899/jrheum.110327.

Association Between Depression and Vascular Disease in Systemic Lupus Erythematosus

CAROL M. GRECO, PhD, TRACY LI, PhD, ABDUS SATTAR, PhD, AMY H. KAO, MD, MPH, NATALYA DANCHENKO, PhD, DANIEL EDMUNDOWICZ, MS, MD, KIM SUTTON-TYRRELL, DrPH, RUSSELL P. TRACY, PhD, LEWIS H. KULLER, MD, DrPH, and SUSAN MANZI, MD, MPH

Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Princeton, New Jersey; Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Medicine, West Penn Allegheny Health System, Pittsburgh, Pennsylvania; Lundbeck SAS, Paris, France; University of Pittsburgh Cardiovascular Institute, Pittsburgh, Pennsylvania; and University of Vermont, Burlington, Vermont, USA

Abstract

Objective—Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with increased prevalence of cardiovascular disease (CVD) and depression. Although depression may contribute to CVD risk in population-based studies, its influence on cardiovascular morbidity in SLE has not been evaluated. We evaluated the association between depression and vascular disease in SLE.

Methods—A cross-sectional study was conducted from 2002–2005 in 161 women with SLE and without CVD. The primary outcome measure was a composite vascular disease marker consisting of the presence of coronary artery calcium and/or carotid artery plaque.

Results—In total, 101 women met criteria for vascular disease. In unadjusted analyses, several traditional cardiovascular risk factors, inflammatory markers, adiposity, SLE disease-related factors, and depression were associated with vascular disease. In the final multivariable model, the psychological variable depression was associated with nearly 4-fold higher odds for vascular disease (OR 3.85, 95% CI 1.37, 10.87) when adjusted for other risk factors of age, lower education level, hypertensive status, waist-hip ratio, and C-reactive protein.

Conclusion—In SLE, depression is independently associated with vascular disease, along with physical factors.

Key Indexing Terms

SYSTEMIC LUPUS ERYTHEMATOSUS; CARDIOVASCULAR DISEASE; DEPRESSION
CALCIFICATION; CAROTID PLAQUE; PSYCHOSOCIAL FACTORS

Copyright © 2012. All rights reserved.

Address correspondence to Dr. C.M. Greco, UPMC Center for Integrative Medicine, 580 South Aiken Ave., Suite 310, Pittsburgh, PA 15232, USA. greco@mupmc.edu.

C.M. Greco, PhD, Department of Psychiatry, University of Pittsburgh School of Medicine; T. Li, PhD, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb; A. Sattar, PhD, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine; A.H. Kao, MD, MPH, Department of Medicine, West Penn Allegheny Health System; N. Danchenko, PhD, Lundbeck SAS; D. Edmundowicz, MS, MD, University of Pittsburgh Cardiovascular Institute; K. Sutton-Tyrrell, DrPH, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine; R.P. Tracy, PhD, University of Vermont; L.H. Kuller, MD, DrPH, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine; S. Manzi, MD, MPH, Department of Medicine, West Penn Allegheny Health System.

Depression and cardiovascular disease (CVD) are among the most prevalent and disabling conditions worldwide, contributing to the global public health burden¹. Patients diagnosed with heart disease are at increased risk for developing depression up to 8 years after medical diagnosis². In populations initially free of cardiac disease, depression increases risk for subclinical atherosclerosis by greater than 2-fold^{3,4}, and risk for incident cardiac events by 50% or more^{5,6}, including a 4.5-fold increased risk for myocardial infarction (MI)⁷. In patients with existing CVD, the presence of depression increases the risk of future cardiac events⁸, and increases risk of mortality up to 5 years following first MI⁹.

Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory autoimmune disease characterized by high rates of both CVD and depression. Young female patients with SLE have a 50-fold increased risk of MI compared to women without lupus¹⁰, and higher than expected rates of stroke and hypertension¹¹. Markers of subclinical atherosclerosis, such as coronary artery calcium (CAC) and carotid plaque, are also more prevalent in women with SLE^{12,13}. These atherosclerotic markers predict future cardiac events in SLE¹⁴ and therefore serve as surrogates for CVD. Notably, although all-cause mortality rates in patients with SLE have decreased in recent decades, CVD-related mortality has not¹⁵. Thus, understanding and treating the risk factors for CVD in SLE is important.

Investigations have shown that traditional CV risk factors such as hypertension, hyperlipidemia, and high body mass index (BMI)^{16,17,18} are associated with increased rates of atherosclerotic changes in SLE. However, the presence of traditional risk factors alone does not fully explain the greatly increased risk for CVD in SLE.

In addition to traditional CVD risk factors, it has been clearly shown that a “lupus factor” related to SLE disease or its treatment is an important contributor to atherosclerotic changes and CVD in SLE^{19,20}. Longterm use of cortico-steroids, high levels of inflammation, and accrued organ damage due to immune activation are some of the potential “lupus factor” candidates contributing to CVD in this group.

Depression may play a role in lupus as well as in CVD. Depression is more prevalent in patients with SLE than in controls and in patients with other inflammatory conditions such as rheumatoid arthritis and ankylosing spondylitis^{21,22,23}. There is some evidence that depression is associated with SLE disease activity^{22,23,24}. Depression is associated with poor medication adherence among SLE patients²⁵ as well as cognitive impairment^{26,27}. Although studies of CVD in SLE frequently include disease-related variables, the potential role of depression has received little attention.

We evaluated psychological as well as biological factors associated with atherosclerosis in SLE, a chronic inflammatory disease with high rates of CVD, mental health concerns, and traditional biological and demographic patterns commonly associated with poor heart health.

MATERIALS AND METHODS

Study population

The participants in this study were women with SLE enrolled in the Heart Effects on Atherosclerosis and Risk of Thrombosis in SLE (HEARTS) investigation, funded by the National Institutes of Health (R01 AR46588). The purpose of the HEARTS study was to compare prevalence and risk factors for coronary artery calcification in women with SLE and healthy controls. The participants had no history of CVD events²⁸ and were nonselectively recruited from the Pittsburgh Lupus Registry, which at the time of enrollment included 983 living participants. The registry includes patients seen at inpatient or outpatient

facilities at the University of Pittsburgh Medical Center or by practicing rheumatologists within the Pittsburgh metropolitan area. All women with SLE were required to fulfill 1982 or 1997 American College of Rheumatology (ACR) revised criteria for the classification of definite or probable SLE^{29,30} and be over the age of 18 years.

All participants completed informed consent procedures. The study was approved by the University of Pittsburgh Institutional Review Board.

Procedures

The study procedures included an interview, completion of a validated depression questionnaire [the Center for Epidemiologic Studies Depression Scale (CES-D)]³¹, physical examination, and laboratory and imaging studies [electron beam computed tomography (EBT) and carotid ultrasound]. Each participant completed the study procedures during a single study visit. Data for this cross-sectional study were collected between March 2002 and September 2005.

Traditional cardiovascular risk factors

Information was collected on age, patient-reported race, education level, smoking habits, family history of CVD (MI, stroke, or sudden death of a first-degree relative before age 60 yrs), waist and hip circumference, and BMI. Blood pressure was determined and hypertension was defined as blood pressure > 140 mm Hg systolic or > 90 mm Hg diastolic or the use of antihypertensive therapy. Fasting blood samples were obtained for standard laboratory testing of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, insulin, albumin, homocysteine, and glucose levels. Insulin resistance was calculated using the homeostatic model formula^{32,33}: $[\text{insulin (mU/l)} \times \text{glucose (nmole/l)}] / 22.5$.

Inflammatory markers

Laboratory assessments of inflammatory markers were conducted using blood samples from the single study visit. Assays were run in batches to reduce analytical variability. Soluble E-selectin (sE-selectin) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured by commercial assays (Parameter Human sE-Selectin Immunoassay and Human sICAM-1 Immunoassay; both from R&D Systems, Minneapolis, MN, USA). High sensitivity C-reactive protein (hsCRP) was quantified by automated particle-enhanced immunonephelometry (BN-II, Siemens Healthcare Diagnostics, Deerfield, IL, USA). Fibrinogen was measured using an automated clot-rate assay (Diagnostica Stago STA-R, Parsippany, NJ, USA)^{34,35} (R.P. Tracy, University of Vermont).

SLE-related factors

Rheumatologists specializing in SLE (AHK, SM) assessed disease activity and cumulative organ damage due to SLE at the study visit. Measures included the revised Systemic Lupus Activity Measure (SLAM-R)³⁶ and the SLE Disease Activity Index (SLEDAI)³⁷. The SLAM-R assesses disease activity in 11 organ systems occurring over the previous month, with possible score range 0–81. The SLEDAI contains weighted descriptors of SLE signs and symptoms present in the past 10 days, and the score can range from 0 to 105. Organ damage due to SLE was measured using the Systemic Lupus International Collaborating Clinics (SLICC) damage index³⁸ with the vascular items removed, yielding a possible score range of 0–36. We also collected information regarding individual criteria for SLE diagnosis and history of steroid use.

Psychosocial assessment

Participants completed the CES-D during the study visit. The CES-D is a validated 20-item self-report instrument used extensively in community samples and medically ill groups, including SLE^{21,39,40,41}. The CES-D items assess past-week symptoms, such as persistent sadness, low motivation, and feelings of worthlessness, that are consistent with a depressive disorder. Although the CES-D is not used to diagnose specific depressive disorders, clinically significant depression is typically defined as a CES-D score > 16 ^{31,42}. We used a CES-D symptom score > 16 as the indicator of clinically significant depression.

Vascular disease endpoint

The vascular disease indicator for the study was a composite consisting of presence of CAC and/or carotid artery plaque. Such composites are accepted practice in atherosclerosis and CV event research^{43,44}. The first step in determining the composite vascular disease indicator was to measure for the presence of CAC using EBT (Imatron C-150 scanner; Imatron, San Francisco, CA, USA). Thirty to forty 3-mm slices starting at the aortic root to the apex of the heart were scanned in all participants at the same point during diastole (80% of the RR interval in the electrocardiogram) during a single breath-hold. The images were scored for calcification using the Agatston method⁴⁵. Presence of CAC was defined as Agatston score > 0 . For carotid artery plaque, the carotid ultrasound methodology has been described¹⁶. A Toshiba SSA-270A scanner (Toshiba, Tustin, CA, USA) equipped with a 5-MHZ linear array imaging probe was used to image the carotid arteries. Sonographers scanned the right and left common carotid artery, carotid bulb, and the first 1.5 cm of the internal and external carotid arteries. Plaque was defined as a distinct area protruding into the vessel lumen that was at least 50% thicker than the surrounding areas. For each area scanned, the degree of plaque was graded 0 (no observable plaque) to 3 (plaque covering 50% of the vessel diameter); grades were summed across the right and left carotid arteries to create an overall measure of focal plaque extent, called the plaque index. The plaque index has been found to be a reproducible and valid measure of carotid atherosclerosis in a number of populations⁴⁶. For the current study, the presence of carotid plaque was defined as plaque index ≥ 1 .

Data analysis

We checked the quality of the data by evaluating the frequency distribution of all relevant variables, and assessed for multicollinearity among the variables. Continuous variables were summarized as mean (SD) and categorical variables as percentages (n). Continuous variables that had skewed distribution, such as waist-hip ratio, were transformed into quartiles. The primary outcome measure was a binary variable indicating vascular disease, defined as presence of CAC and/or carotid artery plaque. Logistic regression was used to evaluate the univariate associations between each of the traditional, inflammatory, psychological, and SLE-related factors and the presence or absence of vascular disease. Variables associated with vascular disease in the univariate analyses were considered for inclusion in the multivariable logistic regression model, based on the variable selection methodology described in Vittinghoff⁴⁷. To select variables for inclusion in multivariable models, we first chose those found to be significant ($p < 0.15$) in unadjusted single predictor models. Each of these variables was evaluated systematically for inclusion in the multivariable logistic regression model⁴⁸, and was retained or removed based upon Akaike information criteria (AIC). The systematic evaluation of variables for inclusion was an iterative process. An example of the iterative process would be starting with important variables such as age and hypertension in the model, inflammatory variables may be added one by one, their significance assessed, and AIC evaluated to determine which inflammatory marker or sets of inflammatory markers fits best in the model or whether they should be removed. Then SLE variables would be considered, one by one, in a similar fashion, and the

model would be evaluated with and without the inflammatory variable or variables. Variable inclusion and removal proceeds in this fashion until all significant univariate variables have been considered. The adequacy of the final multivariable model was evaluated using the specification link test and Hosmer-Lemeshow goodness-of-fit test. SPSS 15 (SPSS Inc., Chicago, IL, USA) and Stata 9 (Intercooled Stata 9.1; StataCorp LP, College Station, TX, USA) were used to perform all statistical analyses. The final model was checked for interaction effects.

RESULTS

Clinical and demographic characteristics

One hundred sixty-one women with SLE were enrolled in the study and completed the assessments. Overall mean age was 50.0 years (SD 10.0); 88% (SD 141) were white, and 55% (SD 89) were hypertensive (defined as using antihypertensive medication or having blood pressure > 140/90 mm Hg). Total cholesterol was 190 mg/dl (SD 41) and waist-hip ratio was 0.85 (SD 0.1). The mean CES-D score was 11.6 (SD 9), with 27% of the sample (43/161 women) scoring at or above 16, a score consistent with clinically meaningful depressive symptoms. Of a possible range of 0–60, the CES-D score ranged from 0 to 45 in the sample overall. We evaluated associations between depression and other characteristics using logistic regression. Older age and being in the second quartile of waist-hip ratio were marginally associated with depression ($p = 0.056$, $p = 0.078$, respectively). Depression was not associated with hypertension, race, education, cholesterol, and steroid use.

SLE characteristics

Disease-related characteristics of the SLE sample are provided in Table 1. The average length of time from SLE diagnosis was 16.3 (SD 7.0) years (range 5–47 yrs). Current SLE disease activity was mild, on average, with mean SLAM-R of 4.5 (SD 2.9, range 0–15), and mean SLEDAI was 2.0 (SD 2.3, range 1–14). Cumulative organ damage scores, i.e., SLICC-ACR Damage Index without vascular items, averaged 1.4 (SD 1.6, range 0–9). Regarding treatment with steroids, the majority of patients (110 of 161) had used steroids, with a median duration of 10 years of use.

Vascular disease and CVD risk factors

Forty-eight percent (SD 77%) of patients showed evidence of CAC, and carotid plaque was found in 36% (SD 58%). The calcium and plaque data are not shown in the tables. One hundred one (63%) of the women showed evidence of vascular disease, defined as presence of coronary calcium and/or carotid plaque. Demographic characteristics and CVD risk factors of SLE patients with and without evidence of vascular disease are shown in Table 2. Several traditional CVD risk factors were associated with vascular disease, including age, years of education, hypertension, adiposity, elevated triglyceride levels, glucose, and insulin resistance. SLE patients with vascular disease had higher mean waist-hip ratios compared to those without vascular disease (0.86 ± 0.1 vs 0.82 ± 0.1 , respectively; $p = 0.03$). Further, those in the highest quartile of waist-hip ratio were more likely to have vascular disease, with an unadjusted OR of 3.99 (95% CI 1.46–10.88; $p = 0.007$). Inflammatory factors related to vascular disease were higher levels of hsCRP, sE-selectin, and fibrinogen. Depression, defined as CES-D depressive symptom score > 16, was more prevalent among SLE women with vascular disease (35%) compared to those without (15%; $p = 0.004$). CES-D scores ranged from 0 to 45 in women with vascular disease, and from 0 to 38 in those without. In terms of SLE disease characteristics, women with SLE who had evidence of vascular disease had greater cumulative damage due to SLE and longer history of corticosteroid use.

The final multivariable model for presence of vascular disease in women with SLE included several traditional cardiovascular risk factors (age, hypertension, years of education), inflammation, adiposity, and depression (Table 3). Women in the highest quartile of waist-hip ratio (> 0.87) were 4 times more likely to have vascular disease, after adjustment for other risk factors. Patients with depression had nearly 4-fold increased odds for vascular disease (OR 3.85, 95% CI 1.37–10.87), independent of traditional risk factors, adiposity, and CRP. Notably, the univariate OR and CI for depression were relatively unchanged after adjustment for the other significant and relevant covariates. This finding indicates that depression has an independent role in CVD. The final model was also checked for interaction effects and there were none.

DISCUSSION

Our results indicate that both psychological and biological factors are associated with vascular disease in women with SLE. Depression is strongly associated with vascular disease, after adjusting for other traditional and inflammatory risk factors. There are several potential pathways that link depression and CVD in SLE. These pathways include possible biological mechanisms, and may also reflect behavioral and environmental influences on health.

Depression is associated with increases in proinflammatory cytokines^{49,50} and the increased CVD risk in depressed persons may be related to added inflammatory burden. A recent case-control study found an elevation in the proinflammatory cytokine interleukin 6 (IL-6) in SLE, and this inflammatory factor was associated with CAC²⁰. The association between depression and inflammation is likely bidirectional⁵¹. An inflammatory environment, which is typically present in patients with SLE, may result in low mood and malaise⁵².

Depressed mood, particularly when chronic, may have a negative influence on lifestyle and behavior choices. For example, depression is a risk factor for poor medication adherence in SLE²⁵ and in adults with heart disease⁵³. Depression may interact with physical inactivity to influence CVD. Murine studies indicate that depressed behavior induced by chronic intermittent stress led to reduced exercise and ultimately to early atherosclerotic changes⁵⁴. In a population study of elderly men, baseline depressive symptoms were associated with physical inactivity. Ten-year risk of cardiac mortality was increased about 50% by the combined effect of depressive symptoms with inactivity⁵⁵.

We considered adiposity as a potential pathway linking depression and vascular disease. Adiposity has received attention in CVD research because adipose tissue, particularly visceral adipose tissue, is known to produce inflammatory factors. In a medically healthy group, depression was found to influence weight accumulation, which led to increased production of inflammatory cytokines⁵⁶. In SLE, obesity was related to increased levels of CRP and IL-6, as well as reduced functional capacity⁵⁷. Our group recently found that BMI mediated an association between depressive symptoms and CAC in SLE⁵⁸. However, in our current study we found that even after adjusting for waist-hip ratio, itself an important risk factor, depression was strongly associated to vascular disease.

In SLE, depression can be a manifestation of central nervous system (CNS) involvement. Although the classification criteria for SLE include only history of seizures or psychosis as the indicators of neurologic involvement³⁰, depression is a component of neuropsychiatric lupus⁵⁹. Mood disorders are included among the 19 central and peripheral neuropsychiatric syndromes listed in the 1999 ACR nomenclature for neuropsychiatric lupus⁶⁰.

Whether depression is linked to CVD in SLE through behavioral pathways, biological pathways, or both remains unresolved. Depression may result from the struggle to cope with

a fatiguing, painful, and unpredictable chronic condition. SLE frequently is associated with work disability and loss of income, which could contribute to depression as well as to reduced ability to access healthcare. Depression and low access to healthcare may both contribute to low adherence with medical treatment, possibly resulting in increased risk of CVD. On the other hand, depression may be a product of the inflammatory milieu of SLE. To the extent that inflammation contributes not only to CVD risk directly but also, on an individual level, to feelings of malaise and low motivation, depression may be a direct consequence of inflammation. However, depression may also add to inflammatory burden through increased sedentary behavior, leading to increased adipose tissue, which is an additional source of inflammation. It is likely that paths linking depression with CVD in SLE are multifactorial as well as bidirectional, and further investigation of these issues is needed.

One limitation of our study is that we did not investigate precisely whether depressive symptoms were directly related to SLE (e.g., a manifestation of CNS lupus) or indirectly related, such as a psychosocial consequence of the life changes brought about by SLE. The cross-sectional design is a limitation that restricts our ability to infer that depression or other risk factors are causally related to vascular disease in SLE. Presumably, vascular changes take place over a long time. Certain risk factors such as adiposity and hypertension may be presumed to be longstanding, but current depressive symptoms may be transient rather than chronic. The CES-D is widely used for quantifying depressive symptoms, in SLE as well as other groups. However, we acknowledge that there are other methods to assess depression, such as the Structured Clinical Interview for the *Diagnostic and Statistical Manual of Mental Disorders*⁶¹. The addition of a diagnostic interview would have the advantage of documenting clinical diagnosis as well as chronicity of depression. Ideally, future studies of the biological and psychological risks for CVD in SLE will include prospective data collection, mood disorder diagnosis in addition to self-report symptoms, and more precise investigation into possible mechanisms linking depression and CVD.

Depression may be associated with premature atherosclerotic disease in SLE through behavioral or biological pathways, or both. In women with SLE, depression is prevalent and is an important influence on physical health and comorbidity in addition to its effect on quality of life. Depression is treatable pharmacologically and through psychotherapy. Attention should be paid to diagnosing and treating depression in SLE, as this should not only contribute to improved quality of life, but possibly improve adherence to medical regimens and physical activity recommendations. Thus, improving management of depression may directly or indirectly influence physical health and overall CVD risk in patients with SLE.

Acknowledgments

Supported by the National Institutes of Health – National Institute of Arthritis, Musculoskeletal and Skin Diseases (K23 AR051314, R01 AR46588-01, K24 AR02213-01, K23 AR051044); National Center for Research Resources/General Clinical Research Center (M01 RR000056); American College of Rheumatology Research and Education Foundation (Health Professional Investigator Award, Physician Scientist Development Award); and Bristol-Myers Squibb.

References

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* 2006; 3:e442. [PubMed: 17132052]
2. Polsky D, Doshi JA, Marcus S, Oslin D, Rothbard A, Thomas N, et al. Long-term risk for depressive symptoms after a medical diagnosis. *Arch Intern Med.* 2005; 165:1260–6. [PubMed: 15956005]

3. Agatista PK, Matthews KA, Bromberger JT, Edmundowicz D, Chang Y, Sutton-Tyrrell K. Coronary and aortic calcification in women with a history of major depression. *Arch Intern Med.* 2005; 165:1229–36. [PubMed: 15956001]
4. Haas DC, Davidson KW, Schwartz DJ, Rieckmann N, Roman MJ, Pickering TG, et al. Depressive symptoms are independently predictive of carotid atherosclerosis. *Am J Cardiol.* 2005; 95:547–50. [PubMed: 15695154]
5. Empana JP, Jouven X, Lemaitre RN, Sotoodehnia N, Rea T, Raghunathan TE, et al. Clinical depression and risk of out-of-hospital cardiac arrest. *Arch Intern Med.* 2006; 166:195–200. [PubMed: 16432088]
6. Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiler D, Ferrieres J, et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Circulation.* 2005; 111:2299–305. [PubMed: 15867179]
7. Eaton, WW.; Fogel, J.; Armenian, HK. The consequences of psychopathology in the Baltimore epidemiologic catchment area follow-up. Eaton, WW., editor. Washington, DC: American Psychiatric Publishing Inc; 2006.
8. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. *Psychosom Med.* 1988; 50:627–33. [PubMed: 2976950]
9. Carney RM, Freedland KE, Steinmeyer B, Blumenthal JA, Berkman LF, Watkins LL, et al. Depression and five year survival following acute myocardial infarction: A prospective study. *J Affect Disord.* 2008; 109:133–8. [PubMed: 18191208]
10. Manzi S, Meilahn E, Rairie J, Conte C, Medsger T, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. *Am J Epidemiol.* 1997; 145:408–15. [PubMed: 9048514]
11. Ward M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. *Arthritis Rheum.* 1999; 42:338–46. [PubMed: 10025929]
12. Roman M, Shanker B, Davis A, Lockshin M, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med.* 2003; 349:2399–406. [PubMed: 14681505]
13. Asanuma Y, Oeser A, Shintai A, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. *N Engl J Med.* 2003; 349:2407–15. [PubMed: 14681506]
14. Elliott JR, Manzi S, Sattar A, Santelices LC, Avram Z, Shaw P, et al. Carotid intima-media thickness and plaque predict future cardiovascular events in women with systemic lupus erythematosus [abstract]. *Arthritis Rheum.* 2008; 58 (Suppl):S413.
15. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. *J Rheumatol.* 2004; 31:713–9. [PubMed: 15088296]
16. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. *Arthritis Rheum.* 1999; 42:51–60. [PubMed: 9920014]
17. Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. *J Rheumatol.* 2006; 33:2458–63. [PubMed: 17014002]
18. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. *J Rheumatol.* 2008; 35:1300–6. [PubMed: 18484694]
19. Esdaile J, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum.* 2001; 44:2331–7. [PubMed: 11665973]
20. Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. *J Rheumatol.* 2006; 33:539–45. [PubMed: 16463434]

21. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. *Arthritis Rheum.* 2006; 55:628–35. [PubMed: 16874786]
22. Sundquist K, Li X, Hemminki K, Sundquist J. Subsequent risk of hospitalization for neuropsychiatric disorders in patients with rheumatic diseases. *Arch Intern Med.* 2008; 65:501–7.
23. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. *Arthritis Care Res.* 2009; 61:822–9.
24. Nery FG, Borba EF, Hatch JP, Soares JC, Bonfa E, Neto FL. Major depressive disorder and disease activity in systemic lupus erythematosus. *Compr Psychiatry.* 2007; 48:14–9. [PubMed: 17145276]
25. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. *Arthritis Rheum.* 2009; 61:240–6. [PubMed: 19177526]
26. Hay EM, Huddy A, Black D, Mbaya P, Tomenson B, Bernstein RM, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. *Ann Rheum Dis.* 1994; 53:298–303. [PubMed: 8017982]
27. Tomietto P, Annese V, D'Agostini S, Venturini P, La Torre G, De Vita S, et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. *Arthritis Care Res.* 2007; 57:1461–72.
28. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. *Ann Epidemiol.* 1995; 5:278–85. [PubMed: 8520709]
29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1982; 25:1271–7. [PubMed: 7138600]
30. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997; 40:1725. [PubMed: 9324032]
31. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Appl Psychol Meas.* 1977; 1:385–401.
32. Kuller LH, Matthews KA, Sutton-Tyrrell K, Edmundowicz D, Bunker CH. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: the Healthy Women Study. *Arterioscler Throm Vasc Biol.* 1999; 19:2189–98.
33. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. *Arthritis Rheum.* 2006; 54:2765–75. [PubMed: 16947779]
34. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. *Clin Chem.* 1997; 43:52–8. [PubMed: 8990222]
35. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. *Clin Chem.* 1995; 41:264–70. [PubMed: 7874780]
36. Liang M, Socher S, Larson M, Schur P. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. *Arthritis Rheum.* 1989; 32:1107–18. [PubMed: 2775320]
37. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum.* 1992; 35:630–40. [PubMed: 1599520]
38. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum.* 1996; 39:363–9. [PubMed: 8607884]
39. Ward MM, Marx AS, Barry NN. Psychological distress and changes in the activity of systemic lupus erythematosus. *Rheumatology.* 2002; 41:184–8. [PubMed: 11886968]
40. Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. *J Rheumatol.* 1998; 25:892–5. [PubMed: 9598886]

41. Trupin L, Tonner MC, Yazdany J, Julian LJ, Criswell LA, Katz PP, et al. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. *J Rheumatol*. 2008; 35:1782–8. [PubMed: 18634153]
42. Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. *Psychol Med*. 1997; 27:231–5. [PubMed: 9122304]
43. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. 2009; 360:1395–407. [PubMed: 19332456]
44. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA*. 2008; 300:2134–41. [PubMed: 18997198]
45. Agatston A, Janowitz W, Hildner F, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol*. 1990; 15:827–32. [PubMed: 2407762]
46. Sutton-Tyrrell K, Wolfson SK, Thompson T, Kelsey SF. Measurement variability in duplex scan assessment of carotid atherosclerosis. *Stroke*. 1992; 23:215–20. [PubMed: 1561650]
47. Vittinghoff, E. Regression methods in biostatistics: Linear, logistic, survival, and repeated measures models. New York: Springer; 2005.
48. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. *Am J Epidemiol*. 1993; 138:923–36. [PubMed: 8256780]
49. Ladwig KH, Marten-Mittag B, Löwel H, Döring A, Keonig W. Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men. *Brain Behav Immun*. 2003; 17:268–75. [PubMed: 12831829]
50. Dinan TG. Inflammatory markers in depression. *Curr Opin Psychiatry*. 2009; 22:32–6. [PubMed: 19122532]
51. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry*. 2010; 67:220–9. [PubMed: 20194822]
52. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. *Trends Immunol*. 2006; 27:24–31. [PubMed: 16316783]
53. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. *Arch Intern Med*. 2005; 165:2508–13. [PubMed: 16314548]
54. Grippo AJ. Mechanisms underlying altered mood and cardiovascular dysfunction: the value of neurobiological and behavioral research with animal models. *Neurosci Biobehav Rev*. 2009; 33:171–80. [PubMed: 18703084]
55. Kamphuis MH, Geerlings MI, Tijhuis MAR, Giampaoli S, Nissinen A, Grobbee DE, et al. Physical inactivity, depression, and risk of cardiovascular mortality. *Med Sci Sports Exerc*. 2007; 39:1693–9. [PubMed: 17909394]
56. Miller GE, Freedland KE, Carney RM, Stetler CA, Banks WA. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. *Brain Behav Immun*. 2003; 17:276–85. [PubMed: 12831830]
57. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. *Arthritis Rheum*. 2005; 52:3651–9. [PubMed: 16258902]
58. Greco CM, Kao AH, Sattar A, Danchenko N, Maksimowicz-McKinnon KM, Edmundowicz D, et al. Association between depression and coronary artery calcification in women with systemic lupus erythematosus. *Rheumatology*. 2009; 48:576–81. [PubMed: 19286698]
59. Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. *Lupus*. 2004; 13:861–4. [PubMed: 15580983]
60. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum*. 1999; 42:599–608. [PubMed: 10211873]

61. First, MB.; Spitzer, RL.; Williams, JBW. Structured clinical interview for DSM-IV (SCID). Washington, DC: American Psychiatric Association; 1987.

Table 1

Characteristics of patients with systemic lupus erythematosus (SLE) (n = 161).

Characteristics	Mean (SD)
Disease duration, yrs	16.3 (7.0)
SLAM-R	4.5 (2.9)
SLEDAI	2.0 (2.3)
SLICC/ACR Damage Index without vascular items	1.4 (1.6)
No. ACR criteria, median (IQR)	5 (4–7)
Skin (malar or discoid rash), %	48
Photosensitivity, %	68.6
Oral ulcer, %	60
Arthritis, %	92
Serositis, %	48
Renal, %	24.5
Central nervous system [*] , %	8
Hematologic, %	54
Immunologic, %	60
ANA positive, %	99

^{*} Diagnostic criteria for CNS lupus include only seizure and psychosis.

IQR: interquartile range; ACR: American College of Rheumatology; CNS: central nervous system; ANA: antinuclear autoantibody; SLAM-R: Systemic Lupus Activity Measure-Revised; SLEDAI: SLE Disease Activity Index; SLICC/ACR: Systemic Lupus International Collaborating Clinics/American College of Rheumatology.

Table 2

Unadjusted logistic regression analysis of covariates of vascular disease in patients with SLE. Covariates with $p < 0.15$ were evaluated for inclusion in multivariable models. Statistically significant differences ($p < 0.05$) between SLE patients with and those without vascular disease are indicated in bold type.

Traditional Risk Factors	Vascular Disease Present*, n = 101	No Vascular Disease*, n = 60	OR (95% CI)	p
Age, yrs	53.5 (9.6)	44.5 (8.0)	1.12 (1.07–1.17)	< 0.001
White, %	87 (88)	90 (54)	0.75 (0.27–2.10)	0.586
Years of education	13.8 (2.4)	15.2 (2.6)	0.80 (0.70–0.92)	0.002
Systolic BP, mm Hg	128.3 (20.0)	109.4 (13.5)	1.07 (1.04–1.10)	< 0.001
Diastolic BP, mm Hg	78.5 (10.3)	73.3 (9.5)	1.05 (1.02–1.09)	0.002
Hypertension [†] , %	64 (65)	38 (23)	2.90 (1.50–5.62)	0.002
Waist-hip ratio, %				
1st quartile	11.9 (12)	23 (14)	—	—
2nd quartile	20.8 (21)	30 (18)	1.36 (0.50–3.68)	0.544
3rd quartile	26.7 (27)	27 (16)	1.97 (0.73–5.29)	0.179
4th quartile	40.6 (41)	20 (12)	3.99 (1.46–10.88)	0.007
Body mass index, kg/m ²	30.2 (6.6)	23.9 (4.1)	1.25 (1.15–1.36)	< 0.001
Ever a smoker, %	40 (40)	30 (18)	1.53 (0.77–3.02)	0.221
Homocysteine, mg/dl	10.8 (4.4)	9.8 (3.4)	1.07 (0.98–1.17)	0.130
Fasting serum glucose, mg/dl	96.1 (25.5)	86.7 (8.9)	1.04 (1.01–1.08)	0.004
Serum albumin, mg/dl	4.5 (0.52)	4.7 (0.45)	0.50 (0.26–0.99)	0.046
Total cholesterol, mg/dl	192.5 (40.8)	186.3 (41.3)	1.00 (0.99–1.01)	0.359
HDL cholesterol, mg/dl	53.6 (17.0)	55.1 (15.5)	0.99 (0.98–1.01)	0.590
LDL cholesterol, mg/dl	111 (35.7)	108.4 (30.96)	1.00 (0.99–1.01)	0.641
Triglycerides, mg/dl	144.6 (91)	114.9 (56.7)	1.01 (1.00–1.01)	0.028
HOMA insulin resistance	4.7 (5.2)	2.6 (1.9)	1.38 (1.11–1.73)	0.004
Inflammatory markers				
hsCRP, mg/dl	5.5 (6.5)	2.9 (4.3)	1.12 (1.03–1.23)	0.010
sICAM-1, ng/ml	302.8 (91.6)	276.8 (108.7)	1.00 (1.00–1.01)	0.112
sE-selectin, ng/ml	51.7 (21.2)	43.6 (20.3)	1.02 (1.00–1.04)	0.023
Fibrinogen, mg/dl	350.3 (84.8)	321 (88.1)	1.00 (1.00–1.01)	0.041
Psychological				
CES-D 16, %	35 (35)	13 (8)	3.45 (1.47–8.06)	0.004
SLE characteristics				
Duration, yrs	16.6 (6.8)	15.7 (7.4)	1.02 (0.97–1.07)	0.418
ACR criteria	5.7 (1.7)	5.5 (1.5)	1.06 (0.87–1.29)	0.581
SLICC damage index, modified ^{††}	1.6 (1.7)	1.0 (1.2)	1.32 (1.04–1.68)	0.023
SLEDAI score	2.0 (2.4)	2.0 (2.1)	1.00 (0.89–1.15)	0.999
SLAM score	4.6 (2.9)	4.5 (2.9)	1.01 (0.90–1.13)	0.833
Steroid use, ever, %	87 (88)	90 (54)	1.40 (0.52–3.77)	0.505
Steroid use, yrs	11.2 (7.6)	8.5 (5.4)	1.07 (1.00–1.13)	0.047

* Mean (SD) are provided for continuous variables, and number (%) for dichotomous variables.

[†] Defined as blood pressure $\geq 140/90$ mm Hg or taking antihypertensive medication.

^{††} The SLICC/ACR damage index was modified by removing vascular items.

SLE: systemic lupus erythematosus; BP: blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA: homeostatic model; hsCRP: high sensitivity C-reactive protein; sICAM-1: soluble intracellular adhesion molecule-1; sE-selectin: soluble E-selectin; CES-D: Center for Epidemiologic Studies-Depression Scale.

Table 3

Multivariable logistic regression analysis of risk factors for vascular disease in women with SLE (n = 161).

Variable	OR (95% CI)	p
Age	1.11 (1.06–1.17)	< 0.001
Years of education	0.82 (0.68–0.99)	0.037
Depression (CES-D 16)	3.85 (1.37–10.87)	0.011
Hypertension	2.50 (1.10–5.66)	0.028
Waist-hip ratio *		
2nd quartile, 0.77 to < 0.814	1.11 (0.32–3.94)	0.867
3rd quartile, 0.814 to < 0.868	2.60 (0.73–9.36)	0.142
4th quartile, 0.868	4.03 (1.12–14.49)	0.032
hsCRP	1.12 (1.01–1.23)	0.029

* Reference group is the first quartile of waist-hip ratio, < 0.77. For definitions, see Table 2.